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Biosynthetic nerve grafts are developed in order to complement or replace autologous nerve grafts for
peripheral nerve reconstruction. Artificial nerve guides currently approved for clinical use are not widely
applied in reconstructive surgery as they still have limitations especially when it comes to critical dis-
tance repair. Here we report a comprehensive analysis of fine-tuned chitosan nerve guides (CNGs)
enhanced by introduction of a longitudinal chitosan film to reconstruct critical length 15 mm sciatic
nerve defects in adult healthy Wistar or diabetic Goto-Kakizaki rats. Short and long term investigations
demonstrated that the CNGs enhanced by the guiding structure of the introduced chitosan film signif-
icantly improved functional and morphological results of nerve regeneration in comparison to simple
hollow CNGs. Importantly, this was detectable both in healthy and in diabetic rats (short term) and the
regeneration outcome almost reached the outcome after autologous nerve grafting (long term). Hollow
CNGs provide properties likely leading to a wider clinical acceptance than other artificial nerve guides
and their performance can be increased by simple introduction of a chitosan film with the same ad-
vantageous properties. Therefore, the chitosan film enhanced CNGs represent a new generation medical
device for peripheral nerve reconstruction.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Treatment of peripheral nerve transection and laceration in-
juries represents a major challenge in reconstructive surgery and
regenerative medicine. Although peripheral nerves are featuredy, Hannover Medical School,
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Ltd. This is an open access article uwith the intrinsic capacity to regenerate, the degree of functional
recovery depends on a number of factors, such as the patient's age
and general condition, the type of nerve, the delay between the
accident causing the injury and the time of surgery, the skills of the
surgeon as well as on the location and length of the nerve injury.
Small defects (<2 cm) between the separated nerve ends in humans
can be bridged by a number of marketed bioartificial hollow con-
duits of various origins or by processed human peripheral nerve
tissue from donors [1]. Treatment of larger defects, however, is still
a field of intensive research with the autologous nerve graft treat-
ment representing the clinical gold standard [2,3]. For the latter, the
grafts are harvested from less important sensory nerves. Regener-
ation and functional recovery across defects of >3 cm in length,
however, are often incomplete due to differences in nerve archi-
tecture (e.g. size of endoneurial tubes) and mismatch in Schwann
cell phenotypes (sensory vs motor nerve peripheral glia cells) [4].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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including donor site morbidity, need of additional surgery and
limited number of available grafts [3,5]. Another condition that can
limit the outcome of any chosen reconstructive therapy for injured
peripheral nerves is generalized peripheral neuropathy, such as
that occurring in diabetes [6]. The number of patients with diabetes
is increasing globally and any innovative technique for peripheral
nerve repair and reconstruction needs to be evaluated not only for
the use in subjects with healthy general conditions, but also for
those with diabetes [6,7]. Current research and development at-
tempts aim therefore to overcome the present obstacles that pre-
vent a widespread use of bioartificial nerve guides, to significantly
increase the length limit that can currently be successfully bridged
with them (max 2.5 cm) [8], and to significantly improve the
achievable level of functional recovery both in generally healthy
and diabetic subjects suffering from traumatic nerve injuries. The
usually accepted maximal defect length for nerve guide repair in
the clinic is 2.5 cm because the surgeon needs to ensure that
regeneration will occur also without the use of autologous nerve
transplantation. The clinical use of nerve guides, however, depends
also on the type of nerve that has to be reconstructed, e.g., small
digital nerves or the larger median or ulnar nerves [9e11]. To
overcome the critical gap lengths, many different attempts have
been evaluated experimentally also in larger animal models like
Beagle dogs with a defect lengths of 3e6 cm [12e14].
We have previously demonstrated that hollow nerve guides
produced from a fine-tuned form of the natural biopolymer chi-
tosan are as effective in peripheral nerve repair as autologous nerve
grafts when bridging 10 mm sciatic nerve gaps in rat experimental
models [15e17]. These nerve guides did further qualify for func-
tional repair of critical length, 15 mm, sciatic nerve defects in a
considerably high percentage of the evaluated rats [18]. In order to
further increase the regeneration outcome, the chitosan nerve
guides have been filled with a neural and vascular regenerative
hydrogel (NVR-Gel) in a non-modified form or additionally
enriched with primary, naïve or genetically modified Schwann cells
overexpressing selected neurotrophic factors. Although supporting
neurite outgrowth in vitro, the NVR-Gel did not provide a growth-
permissive environment in vivo, but rather impaired the regener-
ation process across a 15 mm critical defect. Supplementation of
fibroblast growth factor 2 (FGF-2) overexpressing Schwann cells
was able to partially overcome this obstacle [19].
The aim of the present studywas to apply a simpler intraluminal
modification to the chitosan nerve guides in order to increase the
success of axonal regeneration and enhance functional recovery
across the critical defect length of 15 mm in rat sciatic nerves in
healthy and diabetic rats; the latter with moderate and clinically
relevant blood glucose levels and with a profile resembling type 2
diabetes [6]. We enhanced the chitosan nerve guides by intro-
ducing a longitudinal film made out of the same fine-tuned chito-
san. That a longitudinal guidance structure can increase peripheral
nerve regeneration has earlier been demonstrated [20]. The chi-
tosan film that we used for the purpose of chitosan tube
enhancement has previously demonstrated to be a suitable
biomaterial for Schwann cell attachment and support of sensory
dorsal root ganglion neurite outgrowth in vitro [21].
The potential of chitosan film enhanced chitosan nerve guides
(CFeCNG) to increase peripheral nerve regeneration was evaluated
in three coordinated successive sub-studies. Study I compared the
functional and morphological outcome of peripheral nerve regen-
eration after 15mm sciatic nerve defect reconstructionwith hollow
chitosan nerve guides (hCNG) or 1st generation CFeCNG (contin-
uous chitosan films). In the next step the chitosan films were
modified by introducing holes allowing exchange between the two
compartments of 2nd generation CFeCNG and comprehensive short(Study II) and long-term (Study III) studies were conducted. Study II
evaluated the initially formed regenerated matrix within hCNGs or
CFeCNGs and the regeneration related processes within the dorsal
root ganglia at 56 days after surgery with immunohistochemical
methods. These crucial early events of regeneration were addi-
tionally addressed regarding the differences between generally
healthy and diabetic rats. Study III finally evaluated comprehen-
sively the functional and morphological outcome of peripheral
nerve regeneration in experimental groups including implantation
of (i) hCNG and (ii) 2nd generation CFeCNG, additionally compared
to (iii) autologous nerve grafts (ANGs) and (iv) CFeCNG enriched
with FGF-2 overexpressing Schwann cells (SC-FGF-218kDa). Two
very important results were achieved in our comprehensive ana-
lyses. First, motor recovery was detectable in significantly more
animals in CFeCNG groups than in hCNG groups and the 2nd gen-
eration CFeCNG group demonstrated a significantly better outcome
in this respect than the 1st generation CFeCNG group. While in the
ANG group 100% of the animals demonstrated reinnervation of
proximal as well as distal target muscles this was reached in the
remarkable amount of 86% and 67% of the CFeCNG2nd group. Sec-
ond, and similarly important, 2nd generation CFeCNGs supported
the early regenerative process more than hCNGs and this was
particularly relevant in diabetic rats.
2. Materials and methods
2.1. Manufacturing of chitosan film enhanced chitosan nerve guides
(CFeCNG)
Pandalus borealis shrimp shells served as a source for certified
medical grade chitosan (Altakitin S.A., Lisboa, Portugal). Hollow
chitosan nerve guides (hCNG) with an inner diameter of 2.1 mm
and a length of 19 mm as well as chitosan films (CF) were manu-
factured as described before (Chitosan degree of acetylation ~ 5%;
[15,21]) at Medovent GmbH (Mainz, Germany). ISO 13485 re-
quirements and specifications were applied for all production
steps.
The CFs were cut into a rectangular shape of 15 mm length and
5 mm width. To allow insertion into the conduits, CFs were folded
into a Z-form along their longitudinal axis resulting in kinked edges
of 1.5 mm width pointing into opposite directions (Fig. 1A). Before
being sterilized by electron beam, these films were placed in the
center of chitosan nerve guides leaving 2mmon each side for nerve
end insertion and suturing (Fig. 1B, 1st generation of CFeCNG). For
production of 2nd generation CFeCNGs (Fig. 1CeD), six holes were
introduced along the middle line of the CFs at a distance of 2 mm
between each other by using a sharp needle (0.30  12 mm).
Introduction of the holes was performed in an alternating manner
from both sides to provide similar surface properties at the two
compartments of the CFeCNG.
2.2. Experimental design
Table 1 summarizes the three coordinated successive sub-
studies performed and provides an overview regarding the
respective experimental groups as well as accomplished analyses
after 15 mm rat sciatic nerve defect reconstruction. Study I was
conducted at the Universitat Autonoma de Barcelona (UAB, Spain)
and included two reconstruction conditions: basic hCNGs (group
hCNG-I) or 1st generation CFeCNGs (group CFeCNG1st). The obser-
vation period was 122 days in which functional recovery was
periodically assessed. Study II was executed at University of Lund
(ULUND, Sweden) and included two reconstruction conditions in
generally healthy or diabetic Goto-Kakizaki rats [6]: basic hCNGs or
2nd generation CFeCNGs (groups: hCNG-IIhealthy, hCNG-IIdiabetic;
Fig. 1. Preparation of the different types of nerve guides used. (A) Chitosan films were cut into rectangular shape (length: 15 mm, width: 5 mm) and manually folded into a Z-form.
(BeD) Film placement within basic chitosan conduits (length: 19 mm, inner diameter: 2.1 mm) left about 2 mm space at both ends to allow nerve end insertion and suturing. (B) 1st
generation chitosan film enhanced chitosan nerve guide (CFeCNG) as used in study I. (CeD) 2nd generation CFeCNGs as used in study II and study III with six holes 2 mm distant
from each other. (EeF) Representative photomicrographs taken from CFeCNG2nd seeded with neonatal rat Schwann cells. Top views on a nerve guide after 10 days in vitro (E) or
after 16 days in vitro (F). (GeH) Detail of the Schwann cell seeded chitosan films within the nerve guides illustrating the fish-swarm like growth of the Schwann cells on both
surfaces of the films after 10 days in vitro (G) or 16 days in vitro (H).
C. Meyer et al. / Biomaterials 76 (2016) 33e51 35CFeCNG2nd-healthy; CFeCNG2nd-diabetic). The observation period,
based on pilot experiments, was 56 days in order to assess the
formed regenerative matrix, axonal outgrowth, Schwann cell acti-
vation and apoptosis, as well as activation and neuroprotection of
sensory dorsal root ganglion neurons with immunohistological
techniques. Study III was performed at Hannover Medical School
(MHH, Germany) and included four reconstruction conditions:
autologous nerve grafts (group ANG), basic hCNGs (group hCNG-
III), 2nd generation CFeCNGs (group CFeCNG2nd), and 2nd genera-
tion CFeCNGs enriched with FGF-218kDa overexpressing Schwann
cells (SCs) seeded on both sides of the CF (group CFeCNG2nd-SC-
FGF-218kDa). The observation period was 120 days in which func-
tional recovery was periodically assessed. Study I and Study III were
completed by endpoint histomorphometrical analysis of axonal
regeneration.
2.3. Animals and surgery
The in vivo studies were performed in three different labora-
tories as stated above with different animal breeders and regimes
for anesthesia and analgesia due to different local animal care rules.All animal experiments were approved by the local animal ethical
committees (animal ethics committee in Malm€o [ULUND, Sweden],
Barcelona [UAB, Spain], and Lower-Saxony [MHH, Germany]). In
common, female Wistar rats (225e250 g) and Goto-Kakizaki rats
(GK-rats: kindly provided by Malin Fex, Lund University; around
250 g) were subjected to the experiments and housed in groups of
four animals under standard conditions, with food and water ad
libitum (the diabetic GK rats were provided with extra water).
Fasting blood sugar was measured once a week in the rats at
ULUND from the tail vein (Ascensia contour TM [Bio health Care,
USA, Bio Diagnostics Europe] and LT [Bayer AB, Diabetes Care,
Solna, Sweden]; test slips Microfil TM [Bio Healthcare Diabetes
Care, USA]).
Aseptic conditions, sufficient anesthesia and analgesia were
applied for all surgical procedures and postoperative analgesia was
ensured by appropriate drug application. Animals were prepared
and underwent surgery as described before [15,18]. Briefly,
following exposure at midthigh level, the left sciatic nerve was
transected by a single microscissor cut at a constant point (6 mm
distal to its exit from the gluteus muscle) and a 6 mm segment
removed from the distal nerve end in study I. In studies II and III
Table 1
Overview of the experimental design of the three coordinated successive sub-studies.
Observation
time
Experimental groups N Group name Performed experiments
Study I
(UAB)
120 days Hollow chitosan nerve guide 10 hCNG-I Motor recovery: electrophysiology
non-invasive (60, 90, 120 days);
Sensory recovery: von Frey algesimetry (7, 60, 90,
120 days); Histomorphometry
1st generation chitosan film
enhanced chitosan nerve guide
7 CFeCNG1st
Study II
(ULUND)
56 days Healthy rats:
Hollow chitosan nerve guide
8 hCNG-IIhealthy Analysis of regenerative matrix: presence of axons and
activated and apoptotic Schwann cells by
immunhohistochemistry;
Analysis of sensory dorsal root ganglion activation
by immunohistochemistry
Diabetic GK rats:
Hollow chitosan nerve guide
8 hCNG-IIdiabetic
Healthy rats:
2nd generation chitosan
film enhanced chitosan nerve guide
8 CFeCNG2nd-healthy
Diabetic GK rats:
2nd generation chitosan
film enhanced chitosan nerve guide
8 CFeCNG2nd-diabetic
Study III
(MHH)
120 days Autologous nerve graft 8 ANG Motor recovery: electrophysiology non-invasive
(60, 90 days) and finally invasive (120 days) and
Muscle weight ratio; Sensory recovery: von Frey
algesimetry (7, 60, 90, 120 days); Histomorphometry;
Immunohistochemistry
Hollow chitosan nerve guide 8 hCNG-III
2nd generation chitosan
film enhanced chitosan nerve guide
8 CFeCNG2nd
2nd generation chitosan film
enhanced chitosan nerve guide
with FGF-2 overexpressing
Schwann cells
8 CFeCNG2nd-SC-
FGF-218kDa
C. Meyer et al. / Biomaterials 76 (2016) 33e5136only a 5 mm segment was removed providing an increased length
of the distal nerve end. For nerve reconstruction using the different
types of chitosan nerve guides, the liquid-soaked guides (>30 min
in 0.9% NaCl solution or Schwann cell medium) had a length of
19 mm and bridged a 15 mm defect between the two nerve ends.
The nerve guides were sutured with one epineurial stitch at each
end (9e0, EH7981G, Ethilon, Ethicon, Scotland). For transplantation
of reversed autologous nerve grafts (ANGs) no nerve tissue was
removed, but the distal nerve end again transected 15 mm distal to
the first transection point, flipped (proximal-distal direction) and
turned 180 around its longitudinal axis before three epineurial
sutures were placed with a spacing of 120 from each other.2.4. Preparation of FGF-2 overexpressing Schwann cells for
enrichment of CFeCNGs
Neonatal rat Schwann cells (neoSC) were obtained, cultured and
genetically modified as described before [19,21]. Briefly, sciatic
nerves were harvested from Hannover Wistar rat pups (p1-3) and
neoSC isolated and purified by immunopanning until >90% pure
neoSCs cultures were achieved.
Three days prior to transplantation, neoSCs (passage 8e9) were
genetically modified using the nucleofection technique (Basic glial
cell nucleofection kit and program T-20 of AMAXA II device, LONZA,
Cologne, Germany) to introduce the non-viral plasmid encoding for
FGF-218kDa (pCAGGS-FGF-2-18 kDa-Flag, NCBI GenBank accession
NM_019305.2, 533e994 bp) as described before [19]. Afterwards,
cells were cultured for 24 h on poly-L-lysine-coated 6 well-plates
(SigmaeAldrich, Munich, Germany) with neoSC-specific culture
medium (DMEM, 1% Penicillin/streptomycin, 2 mM L-glutamine,
1 mM sodium pyruvate and 10% fetal calf serum [all PAA Labora-
tories, Coelbe, Germany]) to recover from transfection. On the
following day, the genetically modified neoSCs were seeded on the
central part of CFs within 2nd generation CFeCNGs (CFeCNG2nd-SC-
FGF-218kDa). Therefore, 5  105 cells were suspended in a volume of
30 ml culture medium and 15 ml applied on both sides of the CF.
After 30min to allow cell adhesion, the scaffolds were covered with
culture medium to avoid drying of the nerve guides and incubated
at 37 C in humidified atmosphere with 5% (v/v) CO2 for another24 h. On the next day, the medium was changed to serum free-N2
medium and the cell-seeded nerve guides were again incubated
overnight in preparation for surgery.
5  104 cells were seeded into 24-well plates for analyses of cell
purity and transfection efficiency in corresponding sister cultures
after immunostaining with SC specific a-S100 antibody 1:200
(Dako, Denmark) in phosphate buffered salt solution (PBS)/0.3%
Triton-X-100/5% BSA solution or anti-Flag antibody 1:200 (all Sig-
maeAldrich, Germany) and Alexa 488-labelled goat a-rabbit sec-
ondary (Invitrogen, Germany) antibody or Alexa-555-labelled goat
a-mouse IgG secondary antibody 1:500 (Invitrogen, Germany),
respectively [19]. All cell nuclei were counterstained with DAPI
(1:1000 in PBS, SigmaeAldrich, Germany). The transplanted cells
had a purity of 90.2% S100-þ SCs and 90.1% of the cells were Flag-þ
after nucleofection.
In order to proof that the neoSCs successfully adhered to the
chitosan surfaces and populated the CFs within the nerve guides,
sample CFeCNG2nd were seeded with 5  105 neoSCs and kept in
culture for up to 16 days. Fig. 1EeF shows representative photo-
micrographs taken at day 10 and day 16 in vitro, which clearly
demonstrate that the cells densely populated both surfaces of the
CF in the SC-typical fish-swarm like manner.2.5. Assessment of the regenerative matrix at day 56 after surgery
(study II)
At 56 days after surgery a regenerative matrix, sufficient for
immunohistochemical analyses, was formed in the 15 mm long
nerve defect within the nerve guides. The contents of the conduits
together with the respective proximal and distal nerve ends were
harvested as described before [6,15,17]. Briefly, the tube content
was processed for sectioning using a cryostat and longitudinal
sections at 4 mm thickness were collected on Super Frost® plus glass
slides (Menzel-Gl€aser, Germany). On these sections, immunohis-
tochemistry was performed to evaluate (1) presence of axons by
neurofilament staining (anti-human neurofilament protein, 70 kDa
NF-L [DAKO Glostrup, Denmark], 1:80 in 0.25% Triton-X 100 and
0.25% FCS in phosphate buffered salt solution [PBS]/Alexa Fluor 594
conjugated goat anti-mouse IgG [Invitrogen, Molecular Probes,
C. Meyer et al. / Biomaterials 76 (2016) 33e51 37USA], diluted in 1:500 in PBS), and (2) activated Schwann cells
and apoptotic Schwann cells, respectively, by anti-activating tran-
scription factor 3 (ATF3) and anti-cleaved caspase 3 staining (rabbit
anti-ATF-3 polyclonal antibody [1:200; Santa Cruz Biotechnology,
USA] or anti-cleaved caspase-3 antibody [1:200; Invitro Sweden AB,
Stockholm, Sweden]; both diluted in 0.25% Triton-X 100 and 0.25%
FCS in PBS/Alexa Fluor 488 conjugated goat anti-rabbit IgG [Invi-
trogen, Molecular Probes, USA], diluted in 1:500 in PBS). The
Schwann cells were identified on their location and the oval shaped
nuclei [6,22]. Furthermore, double staining for ATF3 or cleaved
caspase 3 and S-100 was additionally performed as earlier
described and mounted in Vectashield® (Vector Laboratories, Inc.
Burlingame, USA) [17,22]. Finally, the slides were mounted with
40,60-diamino-2-phenylindole DAPI to visualize the nuclei (i.e. for
counting the total number of the cells) and cover slipped.
For analysis, as earlier described [6,15,17], blind-coded sections
were digitized and the presence of outgrowing axons in the formed
matrix inside the conduits was evaluated (i.e. present or non-
present) in three randomly selected sections at two different lo-
cations: in the center of the formed matrix as well as in the distal
nerve segment just distal to the distal suture line. The stained cells
for cleaved caspase-3 and ATF-3were also counted in three sections
(image size 500 400 mm;mean of the three sections calculated for
each rat) at two different levels in the matrix and in the adjacent
sciatic nerve: at 3 mm distal to the proximal nerve suture, in the
center of the formed matrix in the nerve guides and in the distal
segment (see above). The same squares were also used for counting
the total number of DAPI stained cells (no/mm2). The images (20
magnification) were analyzed with NIS elements (Nikon, Japan).
2.6. Assessment of sensory dorsal root ganglia at day 56 after
surgery (study II)
At the same time as the content of the nerve guides was har-
vested, the dorsal root ganglia (DRG) L4 and L5 were collected
bilaterally and processed for cryostat sectioning. Longitudinal sec-
tions (8 mm thickness) were collected on Super Frost® plus glass
slides (Menzel-Gl€aser, Germany) for evaluation of cell activation
(i.e. ATF3) and presence of the neuroprotective substance Heat
Shock Protein 27 (HSP27; [6,23]). The DRG sections were air dried,
washed in PBS for 15 min, and thereafter incubated for ATF-3
immunohistochemistry as described above or incubated with a
primary goat-anti-HSP27 antibody [sc-1048, Santa Cruiz Biotech-
nology, USA; dilution 1:200 in 0.25% Triton-X-100 (SigmaeAldrich,
USA) and 0.25% bovine serum albumin (BSA; SigmaeAldrich, USA)
in PBS overnight at 4 C. The anti-HSP27 antibody was detected
with the secondary Alexa flour 488 donkey anti-goat antibody
(Molecular Probes, Eugene, Oregon, USA; dilution 1:500) in PBS for
2 h at room temperature followed by a further wash with PBS for
3  5 min. Finally, theses sections were cover-slipped with Vecta-
shield® (Vector Laboratories, CA, USA) containing DAPI for coun-
terstaining of the nuclei. Three sections from each DRG were
analyzed for ATF3 and HSP27 staining, respectively, and mean
values were calculated from each rat.
To analyze the presence of ATF3 activated sensory neurons and
the expression of HSP27 in the DRGs, images were captured at 10
magnification with the same equipment and processed as above
followed by import into Image J. ATF3 stained sensory neurons
were quantified as described [24] and expressed as percent of total
number of sensory neurons (i.e. DAPI stained cells). A region of
interest (ROI) covering 75x75 pixels was determined to analyze
HSP27 expression. The tool threshold was used to determine the
immunolabelling with the intensity threshold decided by adding
three times the standard deviation of the background to the mean
intensity (x þ 3  SD). Measurement of the immunostained areawas performed across the entire section and expressed in percent
of the total area of the section; thus, both intensity of neurons and
their satellite cells were included. Furthermore, the HSP27
expression was also expressed as a ratio; i.e. percent HSP27 at the
experimental side divided by the expression on the control side.
2.7. Assessment of functional motor and sensory recovery
2.7.1. Motor recovery: electrophysiological tests
The tests were performed according to previous description
[15,18]. Briefly, the animals were anesthetized and monopolar
needle stimulation electrodes were transcutaneously placed at the
sciatic notch. Single electrical impulses (100 ms duration, supra-
maximal intensity) were applied and the compound muscle action
potentials (CMAPs) were recorded from the tibialis anterior muscle
(TA) and the plantar interosseus muscles (PL). The active recording
electrode was located in the respective muscle belly, the reference
electrode in the second or fourth toe and the ground needle elec-
trode was inserted in the skin at the knee. To ensure a steady body
temperature the animals were placed in a prone position on a
thermostatic blanket. For invasive recordings (final examination in
study III), the sciatic nerves were exposed consecutively on the
lesioned and non-lesioned side and stimulated proximal to the
lesion site using a bipolar steel hook electrode (single electrical
pulses, 100 ms duration, supramaximal, but not exceeding 8 mA).
Recording sites remained as described above. The CMAPs were
recorded and displayed in an EMG apparatus (Sapphyre 4ME,
Vickers Healthcare Co, United Kingdom, at UAB (study I) or Key-
point Portable, Medtronic Functional Diagnostics A/S, Denmark, at
MHH (study III)).
Evaluation parameters included the latency of the arriving sig-
nals and the amplitude ratio (amplitude [mV] recorded from
lesioned side divided by non-lesioned side values). For latency
evaluation all values obtained from animals showing distal muscle
reinnervation were taken into account for statistical tests. If no
evoked CMAPwas detected a 0.00 valuewas noted and included for
statistical analysis in case of the amplitude ratio.
2.7.2. Sensory recovery: mechanical pain threshold assessment (von
Frey algesimetry)
Sensory recoverywas determined via von Frey test as previously
described [18,19,25]. In brief, animals were placed into plastic
compartments located on a metallic mesh grid 15e30 min before
starting the experimental session for habituation. Then, the probe
of a von Frey algesimeter (UAB (study I): Bioseb, Chaville, France;
MHH (study III): IITC Inc, Life Science, USA) was applied for stim-
ulation of the lateral paw area innervated by the tibial and sural
nerve branches of the sciatic nerve. The stimulation force required
to elicit a withdrawal response from the animals was noted in
grams [g] and three measurements per stimulation site were used
to determine a mean value. A cut-off force was set to 40 g, when
either no withdrawal was observed or no active response occurred.
To minimize variations between days, the values are stated in %
compared to data obtained from the non-lesioned, healthy side
calculated by the following formula: lesioned side [g]/non-lesioned
side [g] *100.
In Study I the test was performed 7 days, 21 days, 30 days, 60
days, 90 days, and 120 days after nerve guide implantation. Sub-
sequently, the saphenous nervewas cut and the test was conducted
oncemore on day 122. In Study III the test was performed 7 days, 60
days, 90 days, and 120 days after nerve reconstruction.
For statistical analysis all measured values were used and in case
of no response the cut-off force was included. In the course of Study
I successful recordings from the PL muscle positively correlated
with withdrawal responses seen in von Frey test only after deletion
C. Meyer et al. / Biomaterials 76 (2016) 33e5138of the saphenous nerve function on day 122. This additional surgery
was avoided in Study III and only values obtained from animals
showing PL CMAPs were used for final calculation of sensory re-
covery level, while cut-off forces (40 g) were included for animals
that did not show CMAP.
2.8. Nerve immunohistochemistry and morphometry
2.8.1. Nerve immunohistochemistry
After completion of the final functional tests, animals were
sacrificed and the regenerated nerve tissues with the surrounding
chitosan nerve guides were harvested for further analysis. In study I
the complete nerve guidewas removed from the regenerated nerve
tissue and the macroscopic appearance assessed. In study III, the
entire samples (nerve tissue together with nerve guides) were fixed
in 4% PFA overnight (4 C) for subsequent paraffin-embedding and
(immuno-) histological analysis. Serial 7 mm sections were obtained
(two series of 20 blind-coded sections each, one in the region
without CF and one with CF, each covering a distance of about
630 mm). Sample sections were processed for hematoxylin eosin
(HE) and trichrome (collagen) staining in order to visualize the
tissue within the nerve guides. For the trichrome-staining, sections
were subjected to hematoxylin (Roth, Germany), before being
washed-offed under tap water. Afterwards the slides were incu-
bated in 20 ml staining solution containing acetic acid (1 ml in 99
mlH2O, Merck, Germany) and acetic fuchsin (0.5 g, in 100 ml 1%
acetic acid, Merck, Germany) mixed with 10 ml light green (1 g in
100 ml 1% acetic acid, Chroma Gesellschaft, Schmidt & Co., Ger-
many) and 10 ml wolframate phosphoric acid (1 g in 100 ml H2O,
Merck, Germany). Following a washing step in distilled water, the
slides were subjected to 1% acetic acid, before being pressed with
filter paper, dehydrated, and mounted with corbit-balsam (Hecht,
Germany).
Immunohistology was performed on sections consecutive to the
ones processed for HE or trichrome staining by double-staining for
neurofilament and choline acetyltransferase (ChAT). Therefore, the
sections were incubated in 5% horse serum in PBS for blocking
before incubation with primary goat a-ChAT antibody (1:50, in
blocking solution, AB144P, Millipore, Germany) at 4 C overnight.
Following three washing steps in PBS, incubation with Alexa 555-
conjugated secondary donkey a-goat antibody (1:500, in blocking
solution, A21422, Invitrogen, Germany) for 1 h at RT was performed
and succeeded by another washing round. After a second blocking
step (3% milk powder/0.5% triton X-100 in PBS) overnight incuba-
tion with primary rabbit a-NF200 antibody (against phosphory-
lated NFeH, 1:500, in blocking solution, N4142, SigmaeAldrich,
Germany) was conducted. Three washing steps followed, before
incubation with Alexa 488-conjugated secondary goat a-rabbit
antibody (1:1000, in blocking solution, A11034, Invitrogen, Ger-
many) for 1 h at RT and counterstaining with DAPI (1:2000, in PBS,
SigmaeAldrich, Germany) was performed. Finally, sections were
mounted using Mowiol (Calbiochem, Germany).
For qualitative analysis, representative photomicrographs of HE
and trichromestained sectionswere takenwith thehelpofBX53and
BX51 microscopes and the programs CellSense Dimension and
CellSense Entry (all Olympus, Germany). Immunohistochemistry
images were digitized with the help of a fluorescence microscope
(BX60, Olympus, Germany) and cellP software (Olympus, Germany).
2.8.2. Nerve morphometry
Together with the harvest of the regenerated nerve tissue and
nerve conduits for nerve histology, distal nerve segments (5 mm
segments from distal nerve guide end into distal direction) were
harvested and processed as described before [15,18]. In short, the
tissue was subjected to an initial fixation based on glutaraldehydecontaining fixatives and post-fixed in 1% OsO4. Following dehy-
dration samples were processed for epoxy resin embedding and
semi-thin (2.5 mm) transverse sections were cut in proximal di-
rection using an Ultracut UCT ultramicrotome (Leica Microsystems,
Germany) and stained with toluidine blue. Finally, total myelinated
fiber number, cross sectional area, nerve fiber density, axon diam-
eter, fiber diameter, g-ratio, and myelin thickness were determined
for all experimental groups of study I and study III in addition to
values obtained from healthy control samples. All histo-
morphometry was performed at the University of Turin (UNITO,
Italy) with the help of systematic random sampling as described
before [15].
2.9. Muscle weight ratio
Upon harvest of the nerve tissue samples also the tibialis ante-
rior and gastrocnemius muscles were explanted from study III
animals. The fresh muscle weight from the ipsilateral lesioned side
was then compared to the weight measured from contralateral
healthymuscles to calculate themuscleweight ratio ([g] ipsilateral/
[g] contralateral). The ratios from all animals were included into
statistical analysis irrespectively of the electrodiagnostic or
macroscopic outcome of the nerve regeneration process.
2.10. Statistics
The data obtained in the different experimental settings were
subjected to statistical analysis using KruskaleWallis test or two-
way ANOVA (Analysis of Variance) followed by Dunn's or Tukey's
multiple comparison test or by ManneWhitney U-test (with sub-
sequent Fisher's test; [6]) as specifically indicated in the results
section. Differences concerning expression of HSP27 in DRGs on the
control and experimental sides were examined with the Wilcoxon
signed rank test. The proportion of animals per group that dis-
played a predefined qualitative parameter (evoked CMAP) was
calculated as percentage (0e100%) and analyzed with the Chi-
Square-Test. The p-value was set at < 0.05 as level of significance.
For statistical analysis either the statistical package SPSS (version
17.0 or 20.0, IBM, USA) or GraphPad InStat software, version 5.0.3.0
& 6.00 (Graphpad Software, CA, USA) were used.
3. Results
In the first part of the results section long term study results
obtained from Study I and Study III will be presented. In both
studies, examination of motor and sensory functional recovery and
histo-morphometry were performed over a period of 120 days after
reconstruction of 15mm rat sciatic nerve defects. In the second part
of the results section short term results obtained from Study II will
be presented. Here, the regenerative matrix formed after nerve
guide grafting and the activation of sensory DRG neurons were
immunohistologically analyzed 56 days after reconstruction of
15mm rat sciatic nerve defects in healthy and diabetic rats. Diabetic
Goto-Kakizaki rats could not be subjected to long-term studies
because of their expected limited life-span and ethical approval.
3.1. Long term evaluation of the effects of different reconstruction
approaches on functional recovery and axonal regeneration
The long term evaluations were performed to elucidate the
potential of chitosan film enhanced chitosan nerve guides of the
first (CFeCNG1st, continuous chitosan film, study I) and second
(CFeCNG2nd, chitosan film with holes, study III) generation to sup-
port peripheral nerve regeneration across critical length defects. In
an additional experimental group, CFeCNG2nd were enriched with
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218kDa). Control animals received either nerve reconstruction with
hollow chitosan nerve guides (hCNG-I or hCNG-III, respectively) or
with autologous nerve grafts (ANG).
3.1.1. Electrophysiological assessment
The qualitative results are summarized in Table 2. Non-invasive
electrophysiological recordings did not detect evoked CMAPs
before day 60 after nerve repair.
At this time point, regenerating fibers had reached the TA
muscle in 3 out of 10 hCNG-I animals and in 2 out of 7 CFeCNG1st
animals in study I. At the same examination time point in study III,
reinnervation of the TA muscle did already occur in 7 out of 8 ANG
animals and in none of the other experimental groups. Recordings
from the more distal PL muscle in study I also detected reinner-
vation in the same 3 hCNG-I animals but only in one of the TA-
positive CFeCNG1st animals. In study III, PL muscle reinnervation
was already detectable in 7 out of 7 examinable ANG animals (one
drop out due to events of autotomy), but not in the other groups.
Upon the next examination at day 90 after nerve reconstruction,
additional 1 or 2 animals, respectively, displayed reinnervation of
the TA muscle in study I (Table 2), increasing the percentage of
animals with muscle reinnervation to 40% in hCNG-I group and 57%
in CFeCNG1st group. In study III (Table 2), 100% of ANG animals
displayed TA muscle reinnervation and a gain of motor function
was detectable in hCNG-II animals while CFeCNG2nd caught upwith
the CFeCNG1st animals. In contrast, the number of animals with
detectable reinnervation of PL muscles did not increase in study I in
the hCNG-I group, but a higher percentage of animals demon-
strated motor recovery in the CFeCNG1st group. In study III, PL
muscle reinnervation was started in nerve guide repaired groups,
displaying a slightly better result in the CFeCNG2nd group than in
the hCNG-III group.
At the final examination 120 days after nerve reconstruction
(Table 2), TA and PL CMAPs increased in amplitude but muscle
reinnervation was not found in further animals in study I. In
contrast, TA muscle reinnervation was detected, in final invasive
testing, in an increased number of study III animals of the
CFeCNG2nd as well as the CFeCNG2nd-SC-FGF-218kDa group. Rein-
nervation of PL muscle was detectable in one additional animal of
the CFeCNG2nd group.
When comparing the performance of CFeCNG1st and CFeCNG2nd,
while at 60 days after nerve repair CFeCNG1st performed betterTable 2
Overview of the gain in electrophysiologically detectable motor recovery (evocable compo
Significant differences (p < 0.05) are indicated as follows:þ versus ANG,# hCNG-I versus C
CFeCNG2nd.
60 days 90 day
Animals/
group
Percentage Significant
difference
Anima
group
Tibialis anterior muscle
Study I hCNG-I 3/10 33% þ 4/10
CFeCNG1st 2/7 29% þ 4/7
Study III ANG 7/8 88% 8/8
hCNG-III 0/8 0% þ 2/7
CFeCNG2nd 0/8 0% þ* 4/7
CFeCNG2nd-
SC-FGF-218kDa
0/8 0% þ 0/8
Plantar muscle
Study I hCNG-I 3/10 33% þ 3/10
CFeCNG1st 1/7 14% þ 3/7
Study III ANG 7/7 100% 7/7
hCNG-III 0/8 0% þ 3/7
CFeCNG2nd 0/7 0% þ* 3/6
CFeCNG2nd-
SC-FGF-218kDa
0/6 0% þ 1/6than CFeCNG2nd, at 120 days CFeCNG2nd supported functional
motor recovery in a higher percentage of animals. Additional
enrichment of the CFeCNG2nd with FGF-218kDa overexpressing
Schwann cells did not allow for the level of distal target reinner-
vation displayed in the hCNG and CFeCNG groups.
Quantitative results were calculated for the latencies and
amplitude ratios of the recorded CMAPs at day 120 after nerve
reconstruction and no significant differences between the groups
were detected in study I (non-invasive measurements,
mean ± SEM): TA muscle latency hCNG-I ¼ 4.50 ± 0.82 ms;
CFeCNG1st ¼ 4.05 ± 0.17 ms; TA muscle amplitude ratio hCNG-
I ¼ 16.52 ± 8.10%; CFeCNG1st ¼ 24.80 ± 10.41%; PL muscle latency
hCNG-I ¼ 5.19 ± 0.16 ms; CFeCNG1st ¼ 5.43 ± 0.36 ms; PL muscle
amplitude ratio hCNG-I ¼ 12.86 ± 7.87%; CFeCNG1st ¼ 7.75 ± 4.55%.
Fig. 2 summarizes the quantitative results obtained from study III at
day 120 after nerve reconstruction (invasive measurements). La-
tencies (Fig. 2A) were significantly increased in comparison to
healthy nerve values in the CFeCNG2nd and CFeCNG2nd-SC-FGF-
218kDa groups when CAMPs were recorded from the TAmuscle. This
was also the case for all groups, including ANG and hCNG-III, when
CAMPs were recorded from the PL muscle. TA CMAP amplitude
ratios (Fig. 2B) were decreased in comparison to ANG values in all
nerve guide groups but this difference was significant only for the
hCNG-III and the CFeCNG2nd-SC-FGF-218kDa groups. Due to high
variance, PL CMAP amplitude ratios were significantly lower in
comparison to ANG values only in the CFeCNG2nd-SC-FGF-218kDa
group (Fig. 2B). These quantitative results indicate that not only
muscle reinnervation in general but also the amount of recruited
regenerated fibers in the CFeCNG2nd group approximated that in
the ANG group.
3.1.2. Muscle weight ratio
As an additional indicator for motor recovery, the hindlimb TA
and gastrocnemius (GA) muscles wet weight ratios were deter-
mined in study III. As depicted in Fig. 2C, statistical analysis
revealed again that CFeCNG2nd and ANG group values were not
significantly different from each other, although ANG group had the
highest ratios. Significantly lower muscle weight ratios compared
to ANG group values were detected for the TA muscle and the GA
muscle in the CFeCNG2nd-SC-FGF-218kDagroup, and for the GA
muscle additionally in the hCNG-III group. These results underscore
the relatively good performance of the CFeCNG2nd already detected
in the electrophysiological tests.undmuscle action potentials) during the observation in sub study I and sub study III.
FeCNG1st,x versus CFeCNG2nd, $ versus CFeCNG2nd-SC-FGF-218kDa,* CFeCNG1st versus
s 120 days
ls/ Percentage Significant
difference
Animals/
group
Percentage Significant
difference
40% þ 4/10 40% þ
58% þ# 4/7 58% þ#
100% 8/8 100%
29% þx $ 3/7 43% þx $
58% þ 6/7 86% þ*
0% þx 5/7 71% þx
33% þ 3/10 33% þ
43% þ 3/7 43% þ
100% 7/7 100%
43% þ $ 3/7 43% þx $
50% þ 4/6 67% þ*
17% þx 1/6 17% þx
Fig. 2. Dot plot depicting the latency (A) and amplitude ratio (B) of compound muscle action potentials (CMAPs) recorded during final electrophysiological tests performed 120 days
after nerve surgery in the tibialis anterior muscle (left column) and plantar muscles (right column). (C) Dot plot depicting tibialis anterior muscle (left column) and gastrocnemius
muscle (right column) muscle weight ratios calculated after final electrophysiological measurements. Results were tested for significance (p < 0.05) by KruskaleWallis test, followed
by Dunn's multiple comparison. #p < 0.05, ##p < 0.01, ###p < 0.001 vs healthy control values; *p < 0.05, **p < 0.01 vs ANG group.
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The results obtained for evaluation of sensory recovery using the
von Frey test are summarized in Fig. 3. The withdrawal response
obtained at the healthy contralateral paw was calculated as 100%.
From the injured/regenerating paw two types of withdrawal
response have been recorded, a response at lower force compared
to the contralateral paw (<100%, higher or maladaptive mechano-
sensitivity than normal) or a response at higher force compared to
the contralateral paw (>100%, less mechanosensitivity than
normal).
Study I (Fig. 3A) revealed no withdrawal responses within the
first 21 days following sciatic nerve transection indicating complete
denervation of the animals plantar surface. However, after 30 days,
some animals of both groups (hCNG-I and CFeCNG1st) demon-
strated a withdrawal of the lesioned paw at lower stimulus in-
tensities than seen for the contralateral, intact side. At 60 days after
nerve reconstruction, 7 out of 10 animals from the hCNG-I group
and all animals of the CFeCNG1st displayed withdrawal responses at
low stimulus intensities. During the next examination at 90 days
and 120 days after nerve reconstruction, all animals regardless ofthe received treatment responded to the stimulation at low stim-
ulation intensities. To exclude false positive responses due to
sprouting events from branches of the saphenous nerve [25], this
nerve was then cut and the von Frey test conducted once more on
day 122. At this time point, 4 out of 10 animals (40%) in the hCNG-I
group showed withdrawal responses, resulting in 103 ± 6.57%
response compared to contralateral, and 3 out of 7 animals (43%)
demonstrated a withdrawal response in the CFeCNG1st group,
resulting 117 ± 8.20% response compared to contralateral. These
latter results indicate that the withdrawal responses in previous
test days were in part due to hypersensitivity caused by collateral
spouting of the saphenous nerve and not fully attributable to sciatic
nerve regeneration.
Study III (Fig. 3B) also revealed a gain in mechanosensitivitiy
over time after nerve reconstruction. At 60 days the following
numbers of animals withdrew their paws following lower stimu-
lation intensities than recorded for the contralateral, healthy side:
ANG group: 6 out of 7, hCNG-III group: 4 out of 7, CFeCNG2nd group:
3 out of 6, and none in the other groups. In the course of the study,
additional animals responded to the stimulation. To avoid an
Fig. 3. Results of mechanical pain threshold assessment in the course of Study I and Study III expressed as percentage of values obtained from the contralateral, non-lesioned side.
(A) Results obtained during Study I at various time points. Following 120 days of observation, the saphenous nerve was cut to exclude false positive responses due to saphenous
nerve collateral reinnervation. This resulted in a withdrawal response only from animals that also displayed reinnervation of PL muscles in electrophysiological tests. Results of the
final mechanical pain threshold evaluation are depicted in the last pair of columns (122 days). (B) Results obtained during Study III. The last set of columns (120 days-b) depicts the
calculation corrected according to electrodiagnostic results at the PL muscle level (determined values included for animals with positive CMAP and cut-off values included for
animals without recordable CMAP). Variations in animal numbers are due to exclusions because of autotomy events. Significant differences (p < 0.05) were determined by Two-Way
ANOVA, followed by Tukey's multiple comparisons tests. #p < 0.05; *p < 0.05, **p < 0.01, ***p < 0.001 vs 7 day results within same group; xxp < 0.01, xxxp < 0.001 vs 21 day results
within same group; $ p < 0.05, $$$ p < 0.001 vs 30 day results within same group.
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from animals that showed recordable CMAPs at the PL muscle
during final electrophysiological tests were accepted for the 120
days-b calculation (Fig. 3B last set of columns), while the cut-off
force (40 g, see Section 2.7.2) was included for animals demon-
strating no reinnervation of the PL muscle. Thereby, no significant
differences were detected between the ANG group (84.40 ± 13.70%
response compared to contralateral) and the hCNG-III
(149.50 ± 18.52%) or CFeCNG2nd (104.04 ± 18.87%) groups. The
CFeCNG2nd-SC-FGF-218kDa group (172.90 ± 26.99%) did not display
successful sensory recovery. Overall the values indicate that re-
covery of the mechanosensitivity approximated normal values
most closely in the CFeCNG2nd group.
3.1.4. Macroscopic inspection upon explantation
Prior to nerve tissue harvest for histomorphometrical evalua-
tion, macroscopic observation of the reconstructed nerves in study I
visualized in the hCNG-I group a nerve cable bridging the 15 mm
gap in 5 out of 10 (50%) animals (Fig. 4A). In the CFeCNG1st group,
the bridging tissue was split into two cables and visible in 5 out of 7
(71%) animals (Fig. 4B). The two regenerated tissue cables wereseparated from each other closely proximal to the central CF and
fused again distal to it (Fig. 4B).
In study III all animals of the ANG group showed bridged nerve
ends. Nerve guide repair resulted in the following macroscopically
visible tissue regeneration outcome: hCNG-III group single tissue
cables in 4 out of 7 seven animals (57%); CFeCNG2nd group: two
tissue cables, one in each compartment of the nerve guide, in 7 out
of 7 (100%) animals; CFeCNG2nd-SC-FGF-218kDa group: two tissue
cables, one in each compartment of the nerve guide, in 6 out of 7
animals plus a single cable (in one compartment only) in the last
animal.
The macroscopic inspection demonstrated that nerve regener-
ation through chitosan guides was increased by introducing into
these guides continuous chitosan films (CFeCNG1st) and further
improved by the perforated chitosan films (CFeCNG2nd), while
additional enrichment with FGF-218kDa overexpressing Schwann
cells (CFeCNG2nd-SC-FGF-218kDa) did not provide a synergistic
effect.
3.1.5. Nerve histology
To reveal differences in regenerated tissue organization in study
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guide/nerve tissue samples at mid-graft level (with visible CF in the
respective groups) and at ~1 mm proximal to the distal suture side
(without CF in the respective groups). As shown in Fig. 5, the two
regenerated tissue cables in the CFeCNG2nd and CFeCNG2nd-SC-
FGF-218kDa groups appeared to be connected to each other through
the holes inside the CF. In some cases also small vessels traveling
through the holes were visible with the help of the microsurgical
microscope (Fig. 5AeB). Single histological cross-sections taken
from the mid-graft level and stained for collagen (trichrome
staining) also displayed these connections (Fig. 5CeF), although the
staining procedures partly caused the dissolution of CF out of the
sections. Interestingly, no axons traveling with these tissue bridges
could be detected in neurofilament staining (see below).
Fig. 6 shows representative photomicrographs of HE stained
sections from the ANG group (Fig. 6AeB) or of a regenerated nerve
inside hCNG-III grafts (Fig. 6CeD). Fig. 6EeF demonstrates that two
tissue cables, whichwere separated by the z-shaped CF regenerated
in CFeCNG2nd grafts (Fig. 6E) and fused again prior to reconnecting
to the distal nerve end (Fig. 6F).
Furthermore, consecutive sections were double-stained for
NF200-neurofilament and ChAT to demonstrate the presence of
motor fibers within the regenerated nerve cables. Fig. 7 shows
representative photomicrographs from the ANG group (Fig. 7AeC),
the hCNG-III group (Fig. 7DeF), and the CFeCNG2nd group
(Fig. 7GeH).
3.1.6. Nerve morphometry
Fig. 8 depicts the results of the stereological assessment of the
regenerated myelinated axons in a segment 5 mm distal to the
nerve grafts. The total numbers of myelinated fibers (Fig. 8A) are
significantly different in the ANG group compared to the healthy
nerve, but no differences are detectable between the experimental
groups.
With regard to axon and fiber diameters and myelin thickness
(Fig. 8B), single significant differences from healthy nerve values
could be detected, but again no differences are detectable among
the experimental groups.
These results indicate that once regeneration occurred through
any of the used graft types, axonal regeneration at a short distance
from the graft or guide (in contrast to functional recovery of more
distal targets) follows a similar course in all the reconstruction
conditions assayed.
3.2. Short term evaluation of the regenerative matrix and dorsal
root ganglia
The pre- and postoperative (at 56 days post surgery) blood
glucose levels in the healthy and diabetic GK rats were measured
and are presented in Table 3, with significantly higher values in the
diabetic GK rats. Furthermore it can be revisited in Table 3 that in
contrast to other diabetic animal models these rats developed a
moderate and therefore clinically relevant increase of blood glucoseFig. 4. Harvested regenerated nerve cable 4 months after nerve reconstruction with hollow
(A) A single nerve cable bridging the gap was seen when a hCNG-I had been used for nerve
found after implantation of CFeCNG1st.levels resembling type 2 diabetes in human patients.
3.2.1. Regenerative matrix and distal nerve segment
In single animals we examined the regenerative matrices
formed at earlier time points before 56 days post surgery and found
that then those were not developed enough to allow comprehen-
sive histological analyses (results not shown).
Table 4 summarizes the qualitative and quantitative data as well
as the statistical correlations. At 56 days post surgery, macroscop-
ically, a regenerative matrix was formed completely extending
between the proximal and distal nerve stumps in 6 of 8 animals
(75%) in the hCNG-IIhealthy group and in 4 of 8 animals (50%) in the
hCNG-IIdiabetic group. In groups where CFeCNG2nd had been
implanted, a complete (i.e. connecting the proximal and distal
nerve segments) matrix was formed in 8/8 animals (100%) of both
the CFeCNG2nd-healthy and the CFeCNG2nd-diabetic groups. In these
animals, 6 of 8 (75%) of the CFeCNG2nd-healthy and 7 of 8 (88%)
CFeCNG2nd-diabetic showed a matrix composed of two cables,
extending on each side of the chitosan film, instead of one single
cable as in the hCNG-II samples. Notably, in the CFeCNG2nd guides,
especially in the GK diabetic rats neovascularisation inside and
outside the nerve guides was macroscopically observed.
3.2.1.1. Axonal outgrowth (neurofilament staining). The presence of
axons in the formed matrices was evaluated by neurofilament
staining (Fig. 9). Due to the thin matrix the exact length of axonal
outgrowth was not possible to calculate as previously described
[17]. Axons were present in the center of the formedmatrices in 6/8
(75%) of hCNG-IIhealthyand hCNG-IIdiabetic rats (i.e. axons were also
present in two of the incomplete matrices in the diabetic GK rats;
Table 4). In all rats, where CFeCNG2nd had been implanted, axons
(i.e. 8/8 CFeCNG2nd-healthy and CFeCNG2nd-diabetic rats; i.e. 100%)
were observed in the center of the matrix (Table 4; Fig. 9). The Chi-
squared test did not reveal any differences in presence of neuro-
filaments in the nerve guide among the groups (p ¼ 0.21; Table 4).
Neurofilament staining of the nerve segment distal to the nerve
guides revealed axons in 3/8 (38%) hCNG-IIhealthy rats and in 4/8
(50%) hCNG-IIdiabetic rats, while all rats (100%) in which CFeCNG2nd
had been implanted exhibited axons in the segment just distal to
the nerve guides (Table 4), irrespective of the healthy or diabetic
condition. Thus, the chi-squared test showed a statistical significant
difference in presence of neurofilaments in the distal nerve
segment between the groups (p ¼ 0.005), with differences
observed between reconstructions using the hCNG-II and the
CFeCNG2nd (p ¼ 0.01; Fisher's method; Table 4), but with no dif-
ferences between healthy and diabetic rats.
3.2.1.2. Activated Schwann cells (ATF3-staining). The percentage of
ATF3 stained Schwann cells was evaluated at three locations: 3 mm
from the proximal suture line, at the center of the matrix formed in
the nerve guide and at the distal nerve segment just distal to the
nerve guide [17]. Double staining with S-100 has revealed that the
evaluated cells were Schwann cells [6,17]. In general, few ATF3(hCNG-I) or 1st generation chitosan film enhanced chitosan nerve guides (CFeCNG1st).
reconstruction, while (B) two bridging tissue cables (one in each compartment) were
Fig. 5. (A) Photograph showing an explanted nerve guide from the CFeCNG2nd group. The nerve guide is surrounded by a thin layer of connective tissue and a window has been cut
to visualize two regenerated vascularized tissue cables (black arrows) separated by the chitosan film (CF). (B) The magnification of the white insert drawn in (A), clearly dem-
onstrates the tissue growth (connective tissue and small vessels, black arrows) through the holes in the CF connecting the two regenerated tissue cables. (C, D) Sections subjected to
trichrome-staining (light green) visualizing collagen. Red asterisks mark the regenerated tissue cables that are connected through the holes in the CF. The black inserts have been
further magnified in (E) and (F), respectively. (E) Magnification from insert in (C), the dotted line outlines the tissue bridge between the regenerated cables. (F) Magnification from
insert in (D), the dotted line outlines the tissue bridge between the regenerated cables (marked with red asterisks). CNG: chitosan nerve guide.
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detected between the groups (Table 4) at the three sites. There was
a higher percentage of stained cells in the CFeCNG2nd than in the
hCNG-II samples as well as in the distal nerve segment. Further-
more, there was also higher percentage of stained cells in diabetic
GK rats, except at 3 mm from the proximal suture line.
3.2.1.3. Apoptotic Schwann cells (cleaved caspase 3- staining).
The percentage of cleaved caspase 3 stained Schwann cells (double
stainingwith S-100; [17]) was evaluated at the same locations as for
the ATF3 labeling (Table 4; Fig.10) and showed differences between
the groups at all the locations (KruskaleWallis p ¼ 0.0001; 0.0001;
0.0001, respectively). At 3 mm in the matrix formed in the nerve
guides, therewas higher percentage of stained Schwann cells in the
CFeCNG2nd samples and higher percentage also in the diabetic GK
rats (Table 4). At the center of the nerve guides there were no dif-
ferences between hCNG-II and CFeCNG2nd samples, although the
diabetic GK rats exhibited a higher percentage of apoptotic
Schwann cells. In contrast, the percentages in the distal nerve
segment were lower in the CFeCNG2nd groups as well as lower in
the diabetic GK rats (Table 4; Fisher's test values).
3.2.1.4. Total number of cells (DAPI-staining). The total number of
DAPI labeled cells was also assessed at the three mentioned loca-
tions and showed differences only inside the nerve guides. The
number of DAPI stained cells (i.e. total number of cells) inside the
nerve guides was generally higher in CFeCNG2nd samples as well ashigher in diabetic GK than in healthy rats. No differences between
groups were observed, however, in the distal nerve segment.
3.2.2. Dorsal root ganglia (L4, L5)
Table 5 summarizes the quantitative data as well as the statis-
tical analyses.
3.2.2.1. Activated sensory neurons (ATF3-staining). The sensory
neurons from the control side did not show any staining for ATF3,
while the experimental side showed ATF3 staining to a variable, but
low extent (Table 5), with differences between the groups
(p ¼ 0.002; KruskaleWallis; for details of analysis see Ref. [24]). A
significantly higher percentage of ATF3 labeled sensory neurons
were observed in DRGs from CFeCNG2nd rats, particularly in dia-
betic rats (Table 5).
3.2.2.2. Degree of neuroprotection (HSP27-staining). Accordingly,
HSP27 was observed in DRG from the control side with around
18.0e22.4% of the area stained without any difference between the
groups (Table 5), while the staining on the experimental side was
significantly higher (p ¼ 0.0001 Wilcoxon). Furthermore, a signifi-
cant difference between the experimental groups was observed
concerning the HSP27 staining (Table 5); the expression of HSP27 on
the experimental sidewas again higher in theDRGs from the diabetic
GK rats (Fisher test values; Table 5), without a general difference
between the two types of nerve guides. Accordingly, the HSP27
expression ratio (i.e. experimental/control) revealed also differences
Fig. 6. Representative photomicrographs acquired from histological cross sections obtained at mid-graft level (A,C,E) or at ~1 mm proximal to the distal suture (B,D,F). Sections have
been taken from samples of the ANG group (A,B), the hCNG-III group (C,D), and the CFeCNG2nd group (E,F). Nerve fascicles identified in the HE staining are marked with yellow
asterisks. (A) At mid-graft level an ANG is comprised of one large and one small nerve fascicle, (B) while it is separated into three fascicles in the distal region. (C) At mid-graft level a
thin free floating tissue cable is detectable in hCNG-III, (D) which becomes thicker and separated into more than one fascicle at the distal region. (E) Two tissue cables separated by a
z-shaped CF are visible at the mid-graft region of CFeCNG2nd grafts. (F) The separate tissue cables then fuse to form a single bigger cable containing several nerve fascicles. CNG:
chitosan nerve guide, CF: chitosan film.
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cantly higher values in the CFeCNG2nd and in the diabetic GK rats
(Fisher's test values; Table 5).
4. Discussion
Various conduit designs considering different intraluminal
guidance structures have been experimentally examined for
reconstruction of peripheral nerve defects [1]. Despite thediversity of these designs, however, little progress has been made
in approving a product for clinical use that is able to reach the
level of recovery seen when using the clinical standard treatment
(autologous nerve grafting), especially if the nerve defect exceeds
a critical length of 3 cm in humans [2,4,8]. Consequently, autolo-
gous nerve grafting still remains the surgeons preferred choice for
bridging extended defects between two nerve ends, because this
method gives at least a minimum chance for some functional re-
covery depending on the reconstructed nerve trunk [3]. Several
Fig. 7. Representative photomicrographs acquired from histological cross sections double-stained for neurofilament (NF200, green) and acetylcholine transferase (ChAT, red) and
counterstained with DAPI (blue). The sections have been taken from samples of the ANG group (AeC), the hCNG-III group (DeF), and the CFeCNG2nd group (GeI) at mid-graft level
(A,D,G) or at ~1 mm proximal to the distal suture (C,F,I). White asterisks mark NF-200 immunopositive areas (nerve fascicles). (B,E,H) Merge and magnifications of the three
immunostainings demonstrating nerve fascicle details and the contained regenerated motor axons (yellow).
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autologous nerve grafting and promising results have been ach-
ieved experimentally and some even applied clinically, such as
processed nerve allografts [26e28]. For example, non-
biodegradable poly-sulfon nerve guides enhanced with one elec-
trospun aligned thin film (poly-acrylonitril-co-methylacrylate)
within their lumen were reported to significantly increase pe-
ripheral nerve regeneration across a 14 mm rat sciatic nerve defect
[20]. While these nerve guides have not yet been further advanced
for a possible clinical application, other attempts were made to
enhance already approved nerve guide devices with engineered
neural tissue [29]. For the latter, approved NeuraWrap™ nerve
guides were filled with engineered neural tissue containing adi-
pose derived stem cells and demonstrated to support axonal
regeneration across a 15 mm rat sciatic nerve defect in a short-
term period of 8 weeks after reconstruction to a similar extent
than autologous nerve grafts [29]. Although promising, the neural
engineered tissue and the use of stem cells are not likely to
overcome the regulatory burden for clinical use in the near future
and also the functional outcome of regeneration remains to be
investigated for this type of bioartificial graft. In the recent years
only one engineered nerve guide with intraluminal structures has
been translated into a clinical investigation, the Neuromaix nerve
guide [30] but results are not yet published. This nerve guide is
collagen based and composed of an outer shell conduit filled with
an inner sponge-like conduit, for which the support of functional
recovery across a 2 cm rat sciatic nerve defect has already been
demonstrated [31].
In the present study we evaluated chitosan films as alternative
guidance substrate for regenerating axons within chitosan nerve
guides across an extended rat sciatic nerve defect (15 mm). Thebasic chitosan nerve guides have already been approved for clinical
use in Europe (CE mark, Reaxon® Nerve Guide). This was achieved
after demonstrating their very good pro-regenerative properties in
rat models evaluating standard and critical length nerve defect
reconstruction [15e18]. These nerve guides further provide a high
mechanical strength and collapse stability combined with trans-
parency and easiness to suture them with microneedles [15], thus
making it very likely that these off-the-shelve nerve guides will be
widely accepted when autologous nerve grafting is not the first
option for the surgeon or the patient. The chitosan films used in the
present study to enhance the hollow chitosan nerve guides (hCNGs)
are made under equal ISO standard protocols and out of the same
certified medical grade chitosan. Therefore, only a short period will
be needed until the equally transparent and collapse stable chito-
san film enhanced chitosan nerve guides (CFeCNGs) may be avail-
able for clinical use. With the present results, we show that
CFeCNGs significantly improved nerve regeneration for critical
length defect reconstruction compared to hCNGs. Furthermore, this
higher pro-regenerative effect has been demonstrated not only in
healthy, but also in diabetic rats in which clinically relevant blood
glucose profiles were measured.
The chitosan films were thought to support the fibrin matrix,
which is initially formed upon injury and nerve guide aided nerve
repair [32e34]. Importantly, it is most likely that the incomplete
formation of this fibrin-based cable, or even the lack of formation,
causes failure of regeneration across large defects [2,35]. Within
one week after bridging a 10 mm defect, the fibrin-based cable
connects the two nerve stumps and Schwann cells start to migrate
along it and proliferate to form the bands of Büngner before axonal
sprouts can cross the defect in the axonal phase [2,15,32,34]; again
with a successful axonal outgrowth in diabetic GK rats [17].
Fig. 8. Results of the morphometric analysis of the distal nerve, 5 mm distal to the nerve guide or graft, from Study I and Study III. (A) Total number of regenerated myelinated
axons, total cross sectional area [mm2], and calculated nerve fiber density. (B) Parameters related to axonal maturation: axon diameter, fiber diameter, g-ratio, and myelin thickness.
Data are given in median ± range. Number of analyzed specimens: n ¼ 3: healthy nerve and hCNG-III; n ¼ 4: hCNG-I and CFeCNG1st; n ¼ 6: CFeCNG2nd and CFeCNG2nd-SC-FGF-
218kDa; n ¼ 8: ANG. Results were tested for significance (p < 0.05) using KruskaleWallis test, followed by Dunn's multiple comparison. #p < 0.05 vs contralateral healthy nerve.
C. Meyer et al. / Biomaterials 76 (2016) 33e5146Importantly, it is considered that the absent or incomplete forma-
tion of this fibrin-based cable causes failure of regeneration across
long defects [2,35]. Within one week after bridging a 10 mm defect
in the rat sciatic nerve, the fibrin-based cable connects the twonerve stumps, providing physical support to the migration of fi-
broblasts and Schwann cells along it before axonal sprouts can
cross the gap in the axonal phase [2,15,32]. In the present study
where a 15 mm sciatic nerve defect was bridged with hCNGs or
Table 3
Blood glucose levels in healthy and diabetic Goto-Kakizaki (GK) rats evaluated for up to 56 days post surgery in study II. Values are median [25th (Q1)  75th (Q3) percentiles].
hCNG-IIhealthy CFeCNG2nd-healthy hCNG-IIdiabetic CFeCNG2nd-diabetic p-values (KWa) Fisher's methodb
hCNG-II/CFeCNG2nd Healthy rats/
Diabetic rats
B-glucose (mmol/l) preoperative 4.0 [3.6e4.4] 3.6 [3.3e4.0] 8.7 [8.1e1.2] 7.9 [7.4e8.4] 0.0001 0.68 <0.0001
postoperative 4.1 [3.8e4.49] 4.3 [4.0e4.6] 9.0 [7.7e11.2] 7.7 [7.5e8.7] 0.0001 0.27 <0.0001
a KW ¼ KruskaleWallis.
b Fisher method for independent samples based on the chi square distribution.
Table 4
Nerve regeneration in healthy and diabetic Goto-Kakizaki (GK) rats evaluated 56 days post surgery in study II. Values are median [25th (Q1) 75th (Q3) percentiles].
hCNG-IIhealthy CFeCNG2nd-healthy hCNG-IIdiabetic CFeCNG2nd-diabetic p-values
(KWa)
Fisher's methodb
hCNG-II/
CFeCNG2nd
Healthy rats/
Diabetic rats
Presence of axons
(neurofilament staining;
animals/group)
In nerve guide 6/8 8/8 6/8 8/8 0.21# NA NA
In distal nerve 3/8 8/8 4/8 8/8 0.005# 0.01 1.00
ATF3 - þ Schwann
cells (% of total)
At 3 mm 0.9 [0.5e1.5] 1.5 [1.4e2.7] 0.9 [0.4e1.9] 2.7 [2.3e3.0] 0.004 0.008 0.19
In nerve guide 0.8 [0.7e1.2] 2.8 [2.1e3.0] 1.7 [1.5e2.0] 3.7 [3.0e4.3] 0.0001 <0.0001 0.0002
In distal nerve 1.8 [1.2e3.3] 5.0 [3.9e5.3] 5.4 [4.2e6.3] 7.6 [7.0e10.5] 0.0001 <0.0001 <0.0001
Cleaved caspase-3
- þ Schwann
cells (% of total)
At 3 mm 2.6 [1.8e2.8] 4.6 [4.3e5.4] 3.9 [3.4e4.4] 4.8 [4.6e5.4] 0.0001 0.0001 0.0006
In nerve guide 1.6 [1.3e2.3] 2.2 [1.9e2.6] 3.8 [3.5e4.5] 3.6 [3.3e3.9] 0.0001 0.094 <0.0001
In distal nerve 8.7 [8.2e9.3] 7.6 [7.0e8.1] 7.9 [7.6e8.5] 6.9 [6.4e7.4] 0.0001 0.0002 0.013
DAPI stained cells
(no/mm2)
At 3 mm 862 [806e903] 1016 [999e1063] 1090 [1072e1106] 1070 [1062e1130] 0.0001 <0.0001 <0.0001
In nerve guide 775 [759e796] 923 [904e988] 871 [852e885] 966 [951e987] 0.0001 <0.0001 <0.0001
In distal nerve 1038 [1023e1107] 1051 [1035e1078] 1069 [1057e1089] 1010 [940e1204] 0.57 NA NA
þ ¼ Immunopositive.
NA ¼ Not applicable.
At 3 mm ¼ 3 mm distal to the proximal suture line. In nerve guide ¼ in center of nerve guide. # indicates overall Chi-squared test (Pearson Chi-squared, cross
tabulation > 2  2). The Fishers's method for neurofilament staining is based on subsequent 2  2 cross tabulation Fisher's exact test.
p-values indicating significant differences are set in bold.
a KW ¼ KruskaleWallis.
b Fisher method for independent samples based on the chi square distribution.
Fig. 9. Neurofilament staining in the formed matrix in healthy (A,C) and diabetic GK (B, D) rats repaired with hCNG (A, B) and with CFeCNG2nd (C,D) nerve guides at 56 days post
surgery. Axons (arrows) were present in all CFeCNG2nd nerve guides (8/8 healthy and 8/8 GK rats) as well as in nerve guides of 6/8 hCNG-IIhealthy and 6/8 hCNG-IIdiabetic rats. Scale
bar ¼ 100 mm.
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Fig. 10. Staining for activating transcription factor 3 (ATF3) (AeD) and cleaved caspase 3 (EeH) in the formed matrix in healthy (A, C, E, G) and diabetic GK (B, D, F, H) rats
reconstructed with hCNG (A, B, E, F) or CFeCNG2nd (C, D, G, H) at 56 days post surgery. Arrows indicate stained oval shaped Schwann cells. Scale bar ¼ 100 mm.
C. Meyer et al. / Biomaterials 76 (2016) 33e5148CFeCNGs, a substantial regenerative matrix was found in the sam-
ples taken at 56 days after surgery in both healthy and diabetic rats.
Importantly, the quality of the formed matrix was improved in the
CFeCNG treated animals, and regenerating axons had already
reached the distal nerve segment in a significantly higher propor-
tion at 56 days after surgery, allowing muscle reinnervation
detectable in some cases at 60 days. Furthermore, the regenerative
matrix as well as the nerve segment just distal to the implanted
CFeCNG displayed significantly increased numbers of activated
Schwan cells (ATF3-immunopositive), which are likely to attract
regrowing axons [7,15,24]. Simultaneously, the apoptotic events, asindicated by cleaved caspase 3 immunopositive Schwann cells,
were reduced in nerve segments distal to CFeCNG implants, indi-
cating that also events potentially deleterious for axonal regener-
ation [15] are reduced. The support of axonal regeneration by
CFeCNG is further strengthened by the interesting finding that a
higher number of sensory DRG neurons were found, i.e. ATF3
stained, as well as a larger area was stained for HSP27, as an indi-
cator for increased neuroprotection [6], particularly in the diabetic
GK rats with a moderately increased blood glucose level. It is
conclusive that a higher degree of neuronal protection and activa-
tion together with a higher degree of Schwann cell activation and
Table 5
Analysis of sensory dorsal root ganglia (L4-L5) in healthy and diabetic Goto-Kakizaki (GK) rats evaluated 56 days post surgery in study II. Values are median [25th (Q1) e 75th
(Q3) percentiles].
hCNG-IIhealthy CFeCNG2nd-healthy hCNG-IIdiabetic CFeCNG2nd-diabetic p-values
(KWa)
Fisher's methodb
hCNG-II/
CFeCNG2nd
Healthy rats/
Diabetic rats
ATF3- þ - cells (% of total) Experimental 6.4 [3.9e7.1] 6.9 [5.8e11.9] 6.5 [5.5e8.7] 14.4 [13.3e20.0] 0.002 0.003 0.01
HSP27 expression (% of area) Control 21.3 [18.4e22.8] 18.1 [16.8e20.4] 22.4 [19.0e23.9] 18.0 [16.6e19.7] 0.13 NA NA
Experimental 27.4 [24.8e29.4] 27.3 [25.5e30.5] 30.2 [24.5e32.3] 34.1 [32.1e35.9] 0.023 0.17 0.03
HSP27 Ratio
(experimental/control)
1.35 [1.27e1.54] 1.62 [1.28e1.79] 1.25 [1.10e1.61] 1.83 [1.61e2.13] 0.013 0.003 0.01
þ ¼ Immunopositive.
NA ¼ Not applied.
p-values indicating significant differences are set in bold.
a KW ¼ KruskaleWallis.
b Fisher method for independent samples based on the chi square distribution.
C. Meyer et al. / Biomaterials 76 (2016) 33e51 49reduced apoptosis during the early phase of regeneration can lead
to better functional recovery in the long term.
Usually, when new types of nerve guides or tissue engineered
nerve prostheses are developed, the general health condition of the
tested animals is not considered. The globally increasing number of
patients with diabetes, however, makes it crucial to develop pe-
ripheral nerve reconstruction treatment strategies also suitable for
patients in which neuropathies often occur [7]. Here, we demon-
strate that during the matrix phase axonal regeneration is equally
supported in healthy and diabetic GK rats after critical nerve defect
reconstructed with CFeCNG2nd. With regard to the processes un-
dergoing in the corresponding DRGs, it has been demonstrated
earlier that HSP27 is an important factor preserving nerve function
in diabetic patients [23]. Here we also demonstrate that the HSP27
expression together with that of ATF3 has been found to be
increased in DRGs from diabetic GK rats. In diabetic GK rats, the
regenerative matrix within the nerve guides contained higher
numbers of cells in general and of activated (ATF3-
immunopositive) Schwann cells in particular. With regard to
apoptotic events in Schwann cells we found that those are
increased within the regenerative matrix but not in the distal nerve
segments in diabetic GK rats. In contrast, it has been demonstrated
earlier that Schwann cells in diabetic animals are less responsive to
a nerve injury [36] and that nerves in diabetic animals have a
slower regeneration after end-to-end repair [6]. Therefore the re-
sults obtained in the present study notably indicate that peripheral
nerve reconstruction bymeans of basic or enhanced chitosan nerve
guides represents a promising alternative to standard treatments in
diabetic rats with clinically relevant blood glucose levels.
The pro-regenerative properties of chitosan are well docu-
mented not only for the peripheral and the central nervous system
but also for other applications in regenerative medicine and wound
healing [37e39]. Beside its antimicrobial properties also the
angiogenic properties of chitosan materials are important in the
context of regenerative medicine. Indeed, we observed robust
neovascularization not only in the short term, being even more
evident in the diabetic animals, but also on the long term, where
exclusively in the second generation CFeCNGs (with perforated
chitosan films) small blood vessels traveling through the holes in
the chitosan films were visible. Angiogenesis is important for the
survival of cells and tissue and crucial for the success of peripheral
nerve regeneration across a critical length [40]. In the present
study, long term axonal regeneration, as determined by nerve
morphometry, was similar among all nerve guide conditions
examined. When it comes to functional nerve recovery, however,
the introduction of perforated chitosan films in CFeCNGs was suf-
ficient to further increase the functional outcome compared to
hCNGs. The latter was clearly demonstrated by electrophysiologicalrecording of muscle reinnervation at 120 days after surgery. Im-
plantation of CFeCNGs to bridge the 15 mm sciatic nerve defect
induced higher reinnervation rates of the TA and PL muscles. The
success rates increased by 20e30% in the CFeCNG2nd group
(perforated chitosan film) compared to the CFeCNG1st group
(continuous chitosan film). Regarding the outcome of sensory re-
covery in the present study at 120 days after surgery, study I
revealed less efficiency of implantation of CFeCNG1st compared to
that of hCNG. In contrast, study III revealed the opposite and most
similar recovery in comparison to autologous nerve grafting for the
CFeCNG2nd group. Thus, it can be hypothesized that the perfora-
tions within the chitosan films allowed nutrient interchange be-
tween the two sub-compartments within the second generation
CFeCNGs (also via capillaries connecting the regenerative tissue
along both sides of the chitosan films). This condition probably
supported cell migration and survival across the nerve defect and
formation of the regenerative fibrin matrix to a higher extent than
non-perforated chitosan films used in first generation CFeCNG.
Subsequently 15 mm nerve defect reconstruction with second
generation CFeCNGs resulted in even increased functional recovery.
In study III we included an additional condition, the enrichment
of CFeCNG2nd with FGF-218kDa overexpressing Schwann cells (SC-
FGF-218kDa). It was earlier demonstrated that these cells increase
functional recovery across 15 mm sciatic nerve defects [41] and
even support it when the regeneration process is impaired by local
obstacles such as a too dense hydrogel within chitosan nerve guides
[19]. In the present study CFeCNG2nd-SC-FGF-218kDadid not further
increase the regeneration outcome. The functional recovery was
rather less in comparison to the implantation of cell free
CFeCNG2nd. This indicates that although Schwann cell survival
within the nerve guides previously has been proven in vitro and
neovascularization for nutrient supply in vivo was detectable, the
implanted Schwann cells did not likely survive in vivo and their
debris and metabolites might also interfere with the regrowth of
axons. The Schwann cells have been seeded on non-coated chitosan
films because this has been evaluated previously in vitro [21].
However, in previous studies, where they demonstrated to be
effective, the cells had been suspended in different types of
hydrogels [19,41,42]. Future attempts have to be made to ensure
survival of Schwann cells seeded into CFeCNGs.
5. Conclusions
In the present study, hollow chitosan nerve guides were
enhanced by introduction of chitosan films to increase the regen-
eration outcome across peripheral sciatic nerve defects of critical
length, i.e. 15 mm, in healthy and diabetic rats. This enhanced
chitosan nerve guides not only supported robust axonal
C. Meyer et al. / Biomaterials 76 (2016) 33e5150regeneration and functional recovery in healthy animals but also
demonstrated to be beneficial for the regeneration process in dia-
betic rats with relevant blood glucose levels. Thus, we have an
effective peripheral nerve regenerative device at hand, which
represents an ideal candidate for the translation into the clinic. All
components of the enhanced nerve guides can be produced under
ISO standards. Furthermore, the maintained transparency and the
easiness to suture the device between the nerve ends are likely to
facilitate its wide acceptance among nerve surgeons. Based on the
results presented here, future experiments can now proceed to
address even more complex and challenging conditions for pe-
ripheral nerve reconstruction and recovery, such as the common
conditions of delayed repair or the reconstruction across joints, e.g.
in digital nerve repair.
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